NOT-GM-18-026: Notice of Modification of Eligibility Restriction of PAR-18-265 "Institutional Development Award (IDeA) Program Infrastructure for Clinical and Translational Research (IDeA-CTR)(U54 Clinical Trial Optional)"

Notice of Modification of Eligibility Restriction of PAR-18-265 "Institutional Development Award (IDeA) Program Infrastructure for Clinical and Translational Research (IDeA-CTR)(U54 Clinical Trial Optional)"

Notice Number: NOT-GM-18-026

Key Dates
Release Date: April 19, 2018

Related Announcements
PAR-18-265

Issued by
National Institute of General Medical Sciences (NIGMS)

Purpose

This Notice modifies the eligibility restrictions of PAR-18-265 as follows:

Part 2. Section III.1 Eligible Applicants

Eligible Organizations

Current eligibility:
The following additional restrictions and considerations apply when submitting an application to this FOA:

Institutions (normally identified by a unique NIH IPF number) that currently hold an active NIH-funded clinical and translational center award may not apply. However, these institutions can partner or collaborate with the lead applicant for an IDeA-CTR. For the purposes of this FOA, these awards include the following:

Clinical and Translational Science Award (CTSA) funded by the National Center for Advancing Translational Sciences (NCATS)
Research Centers in Minority Institutions (RCMI) with clinical and translational Research focus (U54 awards) funded by the National Institute on Minority Health and Health Disparities (NIMHD).

IDeA-CTR awards cannot run concurrently with CTSA or RCMI awards with clinical and translational focus. If an institution receives a CTSA or RCMI award after an IDeA-CTR award is funded, the IDeA-CTR award must be relinquished.
Only one IDeA-CTR award can be made per eligible IDeA state. An IDeA-CTR award is expected to be a statewide (and/or interstate) resource and the lead institution must communicate and coordinate with and include other appropriate institutions/organizations within the state when submitting an application.

Modified eligibility:
The following additional restrictions and considerations apply when submitting an application to this FOA:

Institutions (normally identified by a unique NIH IPF number) that currently hold an active NIH-funded clinical and translational center award (e.g. Clinical and Translational Science Award [CTSA] funded by the National Center for Advancing Translational Sciences [NCATS] or Research Centers in Minority Institutions [RCMI] Infrastructure for Clinical and Translational Research [RCTR U54 awards made in response to PAR-13-279] funded by the National Institute on Minority Health and Health Disparities [NIMHD]) may apply but should consider the following restrictions on awards:

IDeA-CTR awards cannot run concurrently with CTSA or RCTR awards. If an institution receives a CTSA or RCTR award after an IDeA-CTR award is funded, the IDeA-CTR award must be relinquished. Conversely, an IDeA-CTR award will not be made while a CTSA or RCTR award is active.

Only one IDeA-CTR award can be made per eligible IDeA state. An IDeA-CTR award is expected to be a statewide (and/or interstate) resource and the lead institution must communicate and coordinate with and include other appropriate institutions/organizations within the state(s) when submitting an application.

All other aspects of this FOA remain the same.

Inquiries

Please direct all inquiries to:

J. Rafael Gorospe, M.D., Ph.D.
National Institute of General Medical Sciences (NIGMS)
Telephone: 301-435-0832
Email: gorospejr@mail.nih.gov